菜单

Services & Solutions
Information Downloads

Harnessing the Transformative Power of Outer Membrane Vesicles to Strengthen the Vaccine Response to MenB
WuXi Vaccines

Despite decades of progress, meningococcal B (MenB) remains a leading cause of invasive disease, with high mortality risk and long-term complications. Since the 1980s, outer membrane vesicle (OMV) vaccines have played a critical role in MenB outbreak responses. Today, advances in gOMVs are creating opportunities for broader, safer protection. Delonix Bioworks’ DX-104, powered by gOMV technology and manufactured by WuXi Vaccines, represents the next step forward in MenB vaccine innovation.

 

Download the white paper to explore the evolution of MenB vaccines, the rise of OMVs, and a glimpse of what comes next for rational vaccine design.

Discuss This White Paper

To discuss the information in this white paper, please complete the form on the following page to connect with our experts.

Connect with our Experts